Skip to main content

Advertisement

Table 1 Demographic and clinical characteristics of early and advanced-stages NSCLC patients in PMC cohort

From: miR-7 methylation as a biomarker to predict poor survival in early-stage non-small cell lung cancer patients

  N = 42 Methylated Unmethylated p-value
PMC cohort: early-stage
Sex
 Female 6 2 (33%) 4 (67%) 1.00
 Male 36 13 (36%) 23 (64%)
Smoking status
 Current smoker 25 9 (36%) 16 (64%) 0.88
 Former smoker 13 5 (38%) 8 (62%)
 Never smoker 4 1 (25%) 3 (75%)
Tumor histologic type
 Adenocarcinoma 24 10 (42%) 14 (58%) n.a
 Squamous 16 3 (19%) 13 (81%)
 Others 2 2 (100%) 0 (0%)
Stage
 IA 2 0 (0%) 2 (100%) n.a
 IB 11 1 (9%) 10 (91%)
 IIA 3 0 (0%) 3 (100%)
 IIB 10 7 (70%) 3 (30%)
 IIIA 16 7 (44%) 9 (56%)
  N = 31 Methylated Unmethylated p-value
PMC cohort: advanced-stage
Sex
 Female 8 6 (75%) 2 (25%) 0.67
 Male 23 17 (74%) 6 (26%)
Smoking status
 Current smoker 11 8 (73%) 3 (27%) 1.00
 Former smoker 20 15 (75%) 5 (25%)
Tumor histologic type
 Adenocarcinoma 15 12 (80%) 3 (20%) n.a
 Squamous 14 10 (71%) 4 (29%)
 Others 2 1 (50%) 1 (50%)
Stage
 IIIB 15 11 (73%) 4 (27%) n.a
 IIIC 2 1 (50%) 1 (50%)
 IV 14 11 (79%) 3 (21%)
RECIST
 PR 10 7 (70%) 3 (30%) n.a
 SD 7 5 (71%) 2 (29%)
 PD 6 6 (100%) 0 (0%)
 n.a. 8   
  1. MiR-7 methylation related to gender, smoking status, tumor histologic type, stage and RECIST. It is not possible to calculate p value because of the number of cases in each group is insufficient
  2. PR partial response, SD stable disease, PD disease progression, n.a. not available